PRPS1/2/PRPS1L1 Polyclonal Antibody
| Code | Size | Price |
|---|
| E-AB-15944-20uL | 20uL | £125.00 |
Quantity:
| E-AB-15944-60uL | 60uL | £172.00 |
Quantity:
| E-AB-15944-120uL | 120uL | £237.00 |
Quantity:
| E-AB-15944-200uL | 200uL | £344.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species:
- Human
- Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Shipping:
Ice packs
Storage:
-20°C
Further Information
Abbreviation:
PRPS1/2/1L1
Background:
PRPS (phosphoribosyl pyrophosphate synthetase) proteins catalyze the synthesis of phosphoribosyl pyrophosphate (PRPP). Three human PRPS isoforms exist and are encoded by three different genes. PRPS1 and PRPS2 (also known as PRS1 and PRS2, respectively) are ubiquitously expressed, while PRPS3 (also known as PRPS1L1) is specific to the testis. PRPP is an important substrate synthesized from MgATP and ribose-5-phosphate in a reaction that requires inorganic phosphate and magnesium as a cofactor. PRPP is essential in the synthesis of nearly all nucleotides, implying that PRPS1/2 play an important role in nucleotide biosynthesis and purine metabolism. A mutation in the gene encoding PRPS1 may result in PRPS superactivity, a disease characterized by gout and the overproduction of purine nucleotides, uric acid and PRPP. PRPS1 mutations can also lead to a reduction in PRPS1 activity resulting in ARTS syndrome or CMTX5 (Charcot-Marie-Tooth disease X-linked recessive type 5).
Buffer:
PBS with 0.05% sodium azide and 50% glycerol, PH7.4
Calculated MW:
35kDa
Concentration:
0.4 mg/mL
Conjugation:
Unconjugated
Dilution:
WB 1:500-1:2000, IHC 1:25-1:100
Immunogen:
Synthetic peptide of human PRPS1/2/1L1
Purification method:
Affinity purification
Target Synonym:
ARTS;DFN2;PRSI;CMTX5;DFNX1;PRS-I;PPRibP/PRSII/PRPS1;PRPS3;PRPSL;PRS-III
UNIProt ID:
P60891,P11908,P21108